Oppenheimer & Co. Inc. Sells 3,280 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Oppenheimer & Co. Inc. reduced its stake in 10x Genomics, Inc. (NASDAQ:TXG – Get Rating) by 16.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,740 shares of the company’s stock after selling 3,280 shares during the period. Oppenheimer & Co. Inc.’s holdings in 10x Genomics were worth $610,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Atlas Capital Advisors LLC increased its holdings in 10x Genomics by 41.7% in the 2nd quarter. Atlas Capital Advisors LLC now owns 935 shares of the company’s stock valued at $42,000 after acquiring an additional 275 shares during the last quarter. Profund Advisors LLC grew its stake in shares of 10x Genomics by 2.9% in the 4th quarter. Profund Advisors LLC now owns 10,663 shares of the company’s stock worth $389,000 after buying an additional 300 shares in the last quarter. CWM LLC grew its stake in shares of 10x Genomics by 48.9% in the 4th quarter. CWM LLC now owns 1,185 shares of the company’s stock worth $43,000 after buying an additional 389 shares in the last quarter. Perigon Wealth Management LLC grew its holdings in 10x Genomics by 6.0% during the 3rd quarter. Perigon Wealth Management LLC now owns 7,166 shares of the company’s stock valued at $204,000 after purchasing an additional 408 shares during the last quarter. Finally, First Horizon Advisors Inc. grew its holdings in 10x Genomics by 64.0% during the 3rd quarter. First Horizon Advisors Inc. now owns 1,220 shares of the company’s stock valued at $34,000 after purchasing an additional 476 shares during the last quarter. 74.34% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on TXG. Barclays began coverage on shares of 10x Genomics in a research report on Wednesday. They issued an “overweight” rating and a $65.00 price objective for the company. UBS Group started coverage on shares of 10x Genomics in a research note on Thursday, February 2nd. They set a “neutral” rating and a $50.00 price objective for the company. Cowen boosted their price objective on shares of 10x Genomics from $52.00 to $57.00 and gave the stock an “outperform” rating in a research note on Thursday, February 16th. Morgan Stanley boosted their price objective on shares of 10x Genomics from $64.00 to $65.00 and gave the stock an “overweight” rating in a research note on Thursday, February 16th. Finally, Stephens initiated coverage on shares of 10x Genomics in a research note on Thursday, March 30th. They set an “overweight” rating and a $65.00 price target on the stock. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, 10x Genomics currently has an average rating of “Moderate Buy” and an average price target of $54.85.

10x Genomics Stock Performance

10x Genomics stock opened at $52.64 on Friday. 10x Genomics, Inc. has a 1 year low of $23.81 and a 1 year high of $56.22. The company’s 50 day simple moving average is $51.57 and its 200-day simple moving average is $43.82. The company has a market capitalization of $6.07 billion, a price-to-earnings ratio of -34.41 and a beta of 1.75.

10x Genomics (NASDAQ:TXG – Get Rating) last posted its earnings results on Wednesday, May 3rd. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.06). 10x Genomics had a negative net margin of 32.51% and a negative return on equity of 22.02%. The firm had revenue of $134.29 million during the quarter, compared to analysts’ expectations of $128.87 million. During the same period in the previous year, the firm posted ($0.38) earnings per share. The firm’s revenue for the quarter was up 17.3% on a year-over-year basis. Equities analysts expect that 10x Genomics, Inc. will post -1.33 earnings per share for the current year.

Insider Buying and Selling

In other 10x Genomics news, CEO Serge Saxonov sold 1,941 shares of the stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $47.75, for a total transaction of $92,682.75. Following the sale, the chief executive officer now owns 909,715 shares in the company, valued at approximately $43,438,891.25. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Serge Saxonov sold 1,941 shares of the stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $47.75, for a total value of $92,682.75. Following the transaction, the chief executive officer now directly owns 909,715 shares of the company’s stock, valued at approximately $43,438,891.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Benjamin J. Hindson sold 1,742 shares of the stock in a transaction on Wednesday, February 22nd. The shares were sold at an average price of $47.75, for a total value of $83,180.50. Following the completion of the sale, the insider now owns 250,237 shares of the company’s stock, valued at $11,948,816.75. The disclosure for this sale can be found here. Insiders have sold a total of 6,928 shares of company stock worth $342,952 in the last quarter. Company insiders own 11.08% of the company’s stock.

About 10x Genomics

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.